Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 0.40 |
| ▸ | S1PR2 known ✓ | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.33 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.32 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.32 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.31 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.31 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.31 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.31 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.31 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.31 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704679 | 0.97 | — | — | |
| SCHEMBL28113559 | 0.82 | ODC1 (0.54) | BLMLMNAKDM4EMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL15268990 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL27721691 | 0.75 | KDM4E (0.39) | BLMLMNAKDM4EMAPTRAB9A | |
| SCHEMBL290961 | 0.75 | — | — | |
| SCHEMBL10892564 | 0.72 | — | — | |
| SCHEMBL15948817 | 0.72 | CES2 (0.48) | ODC1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL6746330 | 0.72 | ACLY (0.32) | S1PR2S1PR4S1PR1S1PR3THRB | |
| SCHEMBL13891313 | 0.71 | ODC1 (0.41) | BLMLMNAKDM4EMAPTRAB9A | |
| Trifluoroacetic Acid SCHEMBL10619788 | 0.71 | HRH4 (0.41) | BLMLMNAKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3109230-B1 | CLASS OF CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN PREPARATION OF PRODRUGS | LI QINGENG (CN) | 2019-11-20 | — | — | EP | disclosed |
| EP-3109229-B1 | WATER-SOLUBLE PROPOFOL DERIVATIVES AND USES THEREOF | JIANGSU NHWALUOKANG PHARMACEUTICAL RES AND DEVELOPMENT CO LTD (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-10239851-B2 | Carboxylic acid derivatives and use thereof in the preparation of prodrugs | Li, Qingeng (CN) | 2019-03-26 | — | — | US | disclosed |
| EP-3109242-B1 | WATER-SOLUBLE TAXANE DERIVATIVES AND USES THEREOF | JIANGSU NHWALUOKANG PHARMCEUTICAL RES AND DEVELOPMENT CO LTD (CN) | 2018-11-07 | — | — | EP | disclosed |
| US-9650390-B2 | Water-soluble taxane derivatives and uses thereof | JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD (CN) | 2017-05-16 | — | — | US | disclosed |
| US-9643917-B2 | Water-soluble propofol derivatives and uses thereof | JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD (CN) | 2017-05-09 | — | — | US | disclosed |
| US-20170057939-A1 | CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN THE PREPARATION OF PRODRUGS | LI, Qingeng (CN) | 2017-03-02 | — | — | US | disclosed |
| US-20170057973-A1 | WATER-SOLUBLE TAXANE DERIVATIVES AND USES THEREOF | JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD (CN) | 2017-03-02 | — | — | US | disclosed |
| US-20170050920-A1 | WATER-SOLUBLE PROPOFOL DERIVATIVES AND USES THEREOF | JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD (CN) | 2017-02-23 | — | — | US | disclosed |
| EP-3109230-A1 | CLASS OF CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN PREPARATION OF PRODRUGS | Li, Qingeng (CN) | 2016-12-28 | — | — | EP | disclosed |
| EP-3109242-A1 | WATER-SOLUBLE TAXANE DERIVATIVES AND USES THEREOF | Jiangsu Nhwaluokang Pharmceutical Research and Development Co. Ltd. (CN) | 2016-12-28 | — | — | EP | disclosed |
| EP-3109229-A1 | WATER-SOLUBLE PROPOFOL DERIVATIVES AND USES THEREOF | Jiangsu Nhwaluokang Pharmceutical Research and Development Co. Ltd. (CN) | 2016-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239851-B2 | Carboxylic acid derivatives and use thereof in the preparation of prodrugs | NR4A3, HCAR3, FFAR3 | ODC1 916/4885S1PR2 877/4885S1PR4 536/4885 |
| US-20170050920-A1 | WATER-SOLUBLE PROPOFOL DERIVATIVES AND USES THEREOF | OPRM1, OPRD1, SIGMAR1 | ODC1 1920/4885S1PR2 899/4885S1PR4 2567/4885 |
| US-20170057973-A1 | WATER-SOLUBLE TAXANE DERIVATIVES AND USES THEREOF | NR5A2, NR5A1, H1-5 | ODC1 2820/4885S1PR2 694/4885S1PR4 574/4885 |
| US-20170057939-A1 | CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN THE PREPARATION OF PRODRUGS | NR4A3, HCAR3, NR4A2 | ODC1 872/4885S1PR2 883/4885S1PR4 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.